Multidrug-resistant tuberculosis in Sierra Leone
- PMID: 35303445
- PMCID: PMC8923690
- DOI: 10.1016/S2214-109X(22)00045-6
Multidrug-resistant tuberculosis in Sierra Leone
Conflict of interest statement
GAY reports personal fees from Pfizer. SL declares no competing interests.
Comment in
-
Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.Lancet Glob Health. 2022 Apr;10(4):e543-e554. doi: 10.1016/S2214-109X(22)00004-3. Lancet Glob Health. 2022. PMID: 35303463 Free PMC article.
Comment on
-
Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.Lancet Glob Health. 2022 Apr;10(4):e543-e554. doi: 10.1016/S2214-109X(22)00004-3. Lancet Glob Health. 2022. PMID: 35303463 Free PMC article.
References
-
- WHO Global Tuberculosis Report 2021. 2021. https://www.who.int/publications/digital/global-tuberculosis-report-2021
-
- The End TB Strategy. 2015. https://tbfacts.org/end-tb/#:~:text=To%20reduce%20TB%20deaths%20by,catas...
-
- Zignol M, Dean AS, Falzon D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016;375:1081–1089. - PubMed
-
- Gibson J. Drug-resistant tuberculosis in Sierra Leone. Tubercle. 1986;67:119–124. - PubMed
-
- Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 2012;205(suppl 2):S228–S240. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources